Evidence map›Paper›PMID 22405262›Full record

ArticleCell transplantation2012

Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth.

Xu Cui, Michael Chopp, Amjad Shehadah, Alex Zacharek, Nicole Kuzmin-Nichols, Cyndy Davis Sanberg, Junhao Dai, Chunling Zhang, Yuji Ueno, Cynthia Roberts and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Models and mechanisms of vascular dementia.Experimental neurology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xu CuiDepartment of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
Michael Chopp
Amjad Shehadah
Alex Zacharek
Nicole Kuzmin-Nichols
Cyndy Davis Sanberg
Junhao Dai
Chunling Zhang
Yuji Ueno
Cynthia Roberts
Jieli Chen
Henry Ford Hospital · USSaneron CCEL Therapeutics (United States) · USOakland University · US

Funding

PREDICTION OF HUMAN BRAIN INFARCTION BY MRIP01NS023393 · NINDS · HENRY FORD HOSPITAL · PI ZHANG, ZHENG GANG · 1986 to 2011
$11.0M
Neurorestorative therapy of stroke with agents that increase HDLR01AG031811 · NIA · HENRY FORD HEALTH SYSTEM · PI CHEN, JIELI · 2009 to 2013
$1.4M
Neuroprotective therapy of stroke with HUCNC and simvastatinR41NS064708 · NINDS · SANERON CCEL THERAPEUTICS, INC. · PI CHEN, JIELI · 2010 to 2010
$177k
NIA NIH HHS R01 AG031811NINDS NIH HHS 1R41NS064708NINDS NIH HHS P01 NS023393NINDS NIH HHS P01 NS23393NINDS NIH HHS R41 NS064708
6 · The paper itself

Abstract

The therapeutic efficacy of cell-based therapy after stroke can be enhanced by making the host brain tissue more receptive to the administered cells, which thereby facilitates brain plasticity. We hypothesized that simvastatin increases human umbilical cord blood cell (HUCBC) migration into the ischemic brain and promotes brain plasticity and neurological functional outcome after stroke. Rats were subjected to 2-h middle cerebral artery occlusion (MCAo) and administered subtherapeutic doses of simvastatin (0.5 mg/kg, gavaged daily for 7 days), HUCBCs (1 × 10(6), one time injection via tail vein), or combination simvastatin with HUCBCs starting at 24 h after stroke. Combination treatment of stroke showed an interactive effect in improvement of neurological outcome compared with simvastatin or HUCBC monotherapy groups. In addition, combination treatment significantly increased brain-derived neurotrophic factor/TrkB expression and the number of engrafted HUCBCs in the ischemic brain compared with HUCBC monotherapy. The number of engrafted HUCBCs was significantly correlated with functional outcome (modified neurological severity score). Combination treatment significantly increased neurogenesis and synaptic plasticity in the ischemic brain, and promoted neuroblast migration in cultured subventricular zone explants. Using primary cultured neurons (PCNs), we found that combination treatment enhanced neurite outgrowth compared with nontreatment control, simvastatin or HUCBC supernatant monotherapy. Inhibition of TrkB significantly attenuated combination treatment-induced neurite outgrowth. Our data indicate that combination simvastatin and HUCBC treatment of stroke increases BDNF/TrkB expression, enhances HUCBC migration into the ischemic brain, amplifies endogenous neurogenesis, synaptic plasticity and axonal growth, and thereby improves functional outcome after stroke.

Indexed as

AnimalsAnticholesteremic AgentsAxonsBrain-Derived Neurotrophic FactorCell MovementCells, CulturedHumansHuman Umbilical Vein Endothelial CellsMaleNeuritesNeurogenesisNeuronsRatsRats, WistarReceptor, trkBSimvastatinAnticholesteremic AgentsBrain-Derived Neurotrophic FactorReceptor, trkBSimvastatin

Identifiers

PMID22405262
PMCPMC3442771
OpenAlexW2080978655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.